Oncotargets and Therapy
Leading citation impact metric from Clarivate Journal Citation Reports
44 papers with at least that number of citations each
State Council for Professorship (HĐGSNN) Scoring
Quyết định số 26/QĐ-HĐGSNN ngày 11/7/2025 (Mục quốc tế)
HĐGSNN Score History
By article publication year| Year | Max Score | Evaluation Details | Source |
|---|---|---|---|
| 2026 | 1.50đ | WoS Q3(IF: 2.4) | 🔵 Computed |
| 2025 | 1.50đ | WoS Q3(IF: 2.8) | 🔵 Computed |
| 2024 | 1.50đ | WoS Q3(IF: 2.7) | 🔵 Computed |
| 2023 | 1.50đ | WoS Q3(IF: 4) | 🔵 Computed |
| 2022 | 1.50đ | WoS Q3(IF: 4.345) | 🔵 Computed |
| 2021 | 1.50đ | WoS Q3(IF: 4.147) | 🔵 Computed |
| 2020 | 1.50đ | WoS Q3(IF: 3.337) | 🔵 Computed |
| 2019 | 1.50đ | WoS Q3(IF: 3.046) | 🔵 Computed |
| 2018 | 1.50đ | WoS Q3(IF: 2.656) | 🔵 Computed |
Note: Domestic journal scores are officially collected from annual HĐGSNN decisions across councils. International journal scores are dynamically computed according to Decision 26/QĐ-HĐGSNN based on quartile and citation metrics in the publication year.
Aims & Scope
OncoTargets and Therapy is an international, peer-reviewed journal focusing on molecular aspects of cancer research, that is, the molecular diagnosis of and targeted molecular or precision therapy for all types of cancer. The journal is characterized by the rapid reporting of high-quality original research, basic science, reviews and evaluations, expert opinion and commentary that shed novel insight on a cancer or cancer subtype. Specific topics covered by the journal include: -Novel therapeutic targets and innovative agents -Novel therapeutic regimens for improved benefit and/or decreased side effects -Early stage clinical trials Further considerations when submitting to OncoTargets and Therapy: -Studies containing in vivo animal model data will be considered favorably. -Tissue microarray analyses will not be considered except in cases where they are supported by comprehensive biological studies involving multiple cell lines. -Biomarker association studies will be considered only when validated by comprehensive in vitro data and analysis of human tissue samples. -Studies utilizing publicly available data (e.g. GWAS/TCGA/GEO etc.) should add to the body of knowledge about a specific disease or relevant phenotype and must be validated using the authors’ own data through replication in an independent sample set and functional follow-up. -Bioinformatics studies must be validated using the authors’ own data through replication in an independent sample set and functional follow-up. -Single nucleotide polymorphism (SNP) studies will not be considered.
SCImago & Scopus Journal Intelligence
Global SCImago ranking, SJR prestige index, Scopus coverage, and societal policy impact
Weighted prestige citation metric per document indexed in the Scopus database.
Measures cumulative publication volume and citation impact.
Average citations received per document published in the 2-year window.
Estimated Article Processing Charge for Open Access publication.
Scopus 3-Year Publication & Citation Window
Aggregated from Scopus database across the 3-year SJR evaluation window.
Societal Impact & Inclusivity (SCImago)
Citations in government and international policy documents
Percentage of female authors published in the journal
Real-world societal policy reach and author gender diversity tracked by SCImago.
Scopus Subject Categories
Chinese Academy of Sciences (CAS) Classification
Major / minor zone classification and CAS Early Warning List history
Publishing & Editorial Information
Detailed publisher, peer-review turnaround, and publication cycle specifications
WoS Categories & Quartiles
Detailed JCR / JCI category rankings and quartile breakdown from Clarivate
| Category | Index | Rank | Quartile |
|---|---|---|---|
BIOTECHNOLOGY & APPLIED MICROBIOLOGY | JCRSCIE | 122/180 | Q3 |
ONCOLOGY | JCRSCIE | 214/333 | Q3 |
BIOTECHNOLOGY & APPLIED MICROBIOLOGY | JCISCIE | 133/180 | Q3 |
ONCOLOGY | JCISCIE | 241/333 | Q3 |
Annual Historical Statistics & Publications
Track annual publication volume, total citations, and Impact Factor evolution
| Year | Impact Factor | Articles / Year | Total Citations |
|---|---|---|---|
| 2026 | — | 77 | 14 |
| 2025 | 2.8 | 104 | 265 |
| 2024 | 2.7 | 142 | 386 |
| 2023 | 4 | 146 | 619 |
| 2022 | 4.345 | 191 | 1,576 |
| 2021 | 4.147 | 532 | 7,245 |
| 2020 | 3.337 | 1,174 | 26,781 |
| 2019 | 3.046 | 1,029 | 26,512 |
| 2018 | 2.656 | 901 | 25,706 |
| 2017 | — | 615 | 17,577 |
| 2016 | — | 803 | 21,223 |
| 2015 | — | 452 | 11,118 |
Journal Metrics & Citation Visualizations
Impact Factor Trend (2018–2024)
Clarivate IF trend for Oncotargets and Therapy
Total Cites vs Self-Cites
Evaluation of scholarly independence and citation reach
Citations per Document
Citation metric windows across 2, 3, and 4 years
Similar Journals in Discipline
Journals in the same research field with comparable impact metrics